Brazil Eyes R$1.5 Billion a Year for GLP-1 Weight-Loss Drugs, Targets Discounts of Up to 90%
Government is betting on local production, greater competition and the purchasing power of Brazil’s public health system to drive down prices.
Government is betting on local production, greater competition and the purchasing power of Brazil’s public health system to drive down prices.
New law sets national healthcare quality standards, requires publication of assessment results and allows daily fines of up to R$500,000.
The first synthetic analogue of Ozempic approved in Brazil uses semaglutide and opens a new front in the multibillion-dollar GLP-1 drug market.
Brazil’s health regulator is waiting for additional safety and efficacy data from Roche before deciding whether the treatment can return to the market.
Rising use of weight-loss pens is cutting alcohol, snacks and dining out — and creating a new spending pattern.
Regulatory gaps in Brazil’s drug market highlight growing risks in safety, compliance, and institutional credibility.
AI governance talks overlap with regulatory accords and Embraer’s bid for multibillion-dollar Indian Air Force contract.
Industry associations representing multinational and domestic drugmakers say patent flexibility could hurt investment and innovation.
Regulatory overhaul broadens administration routes, eases access to THC therapies and marks a milestone for patient treatment.